Lakefront Biotherapeutics (LKFT) EBIT (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported EBIT for 13 consecutive years, with -$72.5 million the latest figure, recorded in Q1 2026.

• Quarterly EBIT rose 59.86% year-over-year to -$72.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $443.9 million (up 316.82% YoY) and the FY2025 annual result came in at $335.7 million, up 256.65% from the prior year.
• EBIT slipped to -$72.5 million in Q1 2026 per LKFT's latest filing, from $861.7 million in the prior quarter.
• Over the last five years, EBIT for LKFT reached as high as $861.7 million in Q4 2025 and fell as low as -$524.2 million in Q3 2025.
• A 5-year average of $14.8 million and a median of -$16.2 million in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2023 — EBIT soared 5332.5% — and 2024, when it slumped 1264.04%.
• Year by year, EBIT stood at $4.6 million in 2022, then surged by 5332.5% to $247.3 million in 2023, then tumbled by 67.19% to $81.1 million in 2024, then jumped by 961.99% to $861.7 million in 2025, then tumbled by 108.41% to -$72.5 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$72.5 million, $861.7 million, and -$524.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.